Listen
TRAJENTA
-
Opinions on drugs -
Posted on
Jun 20 2012
- Updated on
Jul 25 2012
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
| Substantial |
The transparency Committee considers that the actual benefit of the proprietary medicinal product TRAJENTA is substantial in its indications as dual therapy combined with metformin and as triple therapy combined with a sulphonylurea and metformin. |
Clinical Added Value
| no clinical added value |
The Transparency Committee therefore considers that TRAJENTA does not provide any improvement in actual benefit (IAB V) in the management of type 2 diabetes patients as dual oral therapy, combined with metformin and as triple oral therapy, combined with metformin and a sulphonylurea. |
English version
Contact Us
Évaluation des médicaments
